The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
Merck opens first climate-neutral manufacturing facility in Ireland
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Subscribe To Our Newsletter & Stay Updated
